Stefano Festa
A5018969457- Inflammatory Bowel Disease
- Microscopic Colitis
- Neuroendocrine Tumor Research Advances
- COVID-19 Clinical Research Studies
- Immunodeficiency and Autoimmune Disorders
- COVID-19 and healthcare impacts
- Diagnosis and treatment of tuberculosis
- Helicobacter pylori-related gastroenterology studies
- Pregnancy and Medication Impact
- Eosinophilic Esophagitis
- Spondyloarthritis Studies and Treatments
- Tuberous Sclerosis Complex Research
- SARS-CoV-2 and COVID-19 Research
- Gastrointestinal Tumor Research and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Esophageal and GI Pathology
- Gastrointestinal disorders and treatments
- Autoimmune and Inflammatory Disorders Research
- Chronic Lymphocytic Leukemia Research
- Autoimmune and Inflammatory Disorders
- Biosimilars and Bioanalytical Methods
- Diverticular Disease and Complications
- Colorectal Cancer Treatments and Studies
- Liver Diseases and Immunity
- Osteomyelitis and Bone Disorders Research
Ospedale San Filippo Neri
2016-2025
Società Italiana di Reumatologia
2019
Sapienza University of Rome
2009-2018
Azienda Ospedaliera Sant'Andrea
2014-2016
Azienda Ospedaliera S.Giuseppe Moscati
2016
Università Cattolica del Sacro Cuore
2016
Rutgers, The State University of New Jersey
1994
A cure for Crohn's disease (CD), a chronic inflammatory of the gastrointestinal tract unknown etiology, is not available, so patients require lifelong management to keep inflammation under control. The therapeutic armamentarium has expanded with approval several biological drugs, including infliximab, adalimumab, vedolizumab and ustekinumab - monoclonal antibodies that target different pathways darvadstrocel, suspension human allogeneic, adipose-derived, mesenchymal stromal cells treatment...
INTRODUCTION: Patients with ulcerative colitis (UC) receiving immunosuppressive drugs are at substantial risk of colectomy. We aimed to assess the postoperative complications tofacitinib exposure before colectomy in comparison biologics. METHODS: A multicenter, retrospective, observational study was conducted patients UC who underwent total for medically refractory disease, exposed or a biologic surgery. Primary outcome occurrence any complication within 30 (early) and 90 (late) days after...
Abstract Background Risankizumab has been recently approved for the treatment of moderate-to-severe Crohn's disease (CD). It is a humanized IgG1 monoclonal antibody that binds to p19 subunit IL-23, selectively inhibiting IL-23. Due limited available real-world data on its effectiveness, this study aims assess short-term effectiveness and safety risankizumab induction in large, real-life Italian cohort CD patients. Methods From September 2023, following AIFA reimbursement, until now, all...
Abstract Background In a 6-year, multicenter, prospective nested case–control study, we aimed to evaluate risk factors for incident cancer in inflammatory bowel disease (IBD), when considering clinical characteristics of IBD and immunomodulator use. The secondary end point was provide characterization types. Methods All cases occurring patients from December 2011–2017 were prospectively recorded 16 Italian Group the Study Inflammatory Bowel Disease units. Each with new diagnosis matched 2...
The management of moderate to severe ulcerative colitis has undergone significant changes over the past 15 years due regulatory approval several new drugs. In particular, following first biological, i.e. infliximab, a number further biological drugs, such as adalimumab, golimumab, vedolizumab and ustekinumab, small molecules, tofacitinib, have been approved, thus enriching therapeutic armamentarium for colitis. Choice therapy must take into consideration not only need induce maintain disease...
Abstract Background Whether using immunosuppressors (ISS) or biologics after a diagnosis of cancer in Inflammatory Bowel Disease (IBD) patients (pts) may increase the risk new recurrent is undefined. Primary aim: to assess frequency new/recurrent IBD pts treated with ISS and/or cancer. Secondary aims: evaluate same population cancer-related mortality and factors for recurrence malignancy. Methods In retrospective multicentre Italian study, clinical records all were reviewed. Inclusion...
Abstract Background The efficacy of Tofacitinib (TOFA) in several rheumatic diseases led to expectations on a possible benefit this drug for the treatment ulcerative colitis (UC)-associated spondyloarthropathy (SpA). Methods Real-world Effectiveness Ulcerative Colitis Associated Spondyloarthropathy (RETUCAS) is prospective, multicentre, observational study designed assess effectiveness TOFA UC-associated SpA and promoted by Italian Group Inflammatory Bowel Disease (IG-IBD). Patients with UC...
Abstract Background Isolated perianal fistulae (IPAF) without concurrent luminal disease is an uncommon presentation of Crohn’s (CD), posing unique diagnostic and management challenges. IPAF in CD often show complex features, such as secondary tracts abscesses, respond poorly to standard treatments for crypto-glandular fistulae1. Data on the natural history, progression disease, effective remain limited. This study examines contemporary evaluation, clinical course, outcomes patients with...
Abstract Background The best maintenance therapy after a steroid-responsive acute severe ulcerative colitis (ASUC) episode remains poorly studied and is not addressed in current guidelines. We aimed to compare the impact of different treatment strategies following hospitalization for ASUC. Methods Multicentric, multinational, retrospective cohort study including patients hospitalized with ASUC, between 2010-2021, who responded intravenous steroids (Oxford Criteria). Patients were categorized...
Interstitial lung [ILD] disease and granulomatous [GLD] are rare respiratory disorders that have been associated with inflammatory bowel [IBD]. Clinical presentation is polymorphic aetiology unclear.This was an ECCO-CONFER project. Cases of concomitant ILD or GLD IBD, drug-induced ILD/GLD, were collected. The criteria for diagnosing based on definitions from the American Thoracic Society European Respiratory discretion reporting clinician.We identified 31 patients ILD. majority had...
The long-term course of ulcerative colitis after a severe attack is poorly understood. Second-line rescue therapy with cyclosporine or infliximab effective for reducing short-term colectomy but the impact in controversial.
Hepatitis E virus (HEV) is the most important causative agent of acute hepatitis in developing countries. The disease usually characterized by a self-limiting, benign course. However, when particular conditions coexist (pregnancy, old age, pre-existing liver disease) it may run an unfavourable To date, 4 HEV genotypes have been described. Historically, Western world, infection was considered travel-related disease, however last 2 decades great number non-travel-related autochthonous cases...
•The use of ICIs is associated with an increased risk developing different forms colitis.•The 12-month clinical outcome ICI-induced colitis and the factors lack remission are poorly known.•A Crohn's disease-like pattern was a worse rate.•Having histopathological signs microscopic better rate. BackgroundData regarding patients immune checkpoint inhibitor (ICI)-induced scant. We aimed to describe colitis.Materials methodsThis retrospective, European, multicentre study....